1202704-61-7

Basic information

• Product Name: 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate
• Synonyms: 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate
• CAS NO: 1202704-61-7
• Molecular Weight: 388.285
• Mol File: 1202704-61-7.mol

Chemical Properties

• CAS DataBase Reference: 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate(1202704-61-7)
• EPA Substance Registry System: 1,2-diamino-4-bromopyridin-1-ium-2,4,6-trimethylbenzenesulfonate(1202704-61-7)

Safety Data

• Hazardous Substances Data: 1202704-61-7(Hazardous Substances Data)

Upstream product

• 773-64-8 2-mesitylenesulphonyl chloride 
• 84249-14-9 2-amino-4-bromopyridine 
• 56830-76-3 (2,4,6-trimethylbenzenesulfonyl)carbamic acid tert-butyl ester 
• 36016-40-7 mesitylenesulfonylhydroxylamine 

Downstream Products

• 1053655-66-5 7-bromo-[1,2,4]triazolo[1,5-a]pyridine 
• 1202701-61-8 (R)-3-(3-fluoro-4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl)-5-([1,2,3]triazol-1-yl)methyloxazolidin-2-one 
• 1380331-36-1 ethyl 7-bromo-[1,2,4]triazolo[1,5-a]pyridine-2-carboxylate 
• 1380331-74-7 7-bromo-2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridine 
• 1380331-12-3 7-bromo-2-phenyl-[1,2,4]triazolo[1,5-a]pyridine 
• 1380331-40-7 7-bromo-2-isopropyl-[1,2,4]triazolo[1,5-a]pyridine 
• 1380330-53-9 4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid [2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-amide 
• 1380331-75-8 [2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-yl]-carbamic acid tert-butyl ester 
• 1380331-76-9 2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-ylamine 
• 1380331-77-0 5-[2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl]-1-methyl-1H-pyrazole-4-carboxylic acid ethyl ester 
• 1380331-78-1 5-[2-(3-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl]-1-methyl-1H-pyrazole-4-carboxylic acid 
• 1380329-76-9 1-methyl-5-(2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid methyl ester 
• 1380329-77-0 1-methyl-5-(2-phenyl[1,2,4]triazolo[1,5-a]pyridin-7-ylcarbamoyl)-1H-pyrazole-4-carboxylic acid 
• 1380329-78-1 4-(azetidine-1-carbonyl)-2-methyl-2H-pyrazole-3-carboxylic acid (2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)amide 

Relevant articles and documents

USE OF A PHOSPHODIESTERASE 10 INHIBITOR FOR THE TREATMENT OF TOURETTE SYNDROME

Provided herein are methods of treating Tourette Syndrome in a subject in need thereof by administering to the subject compositions comprising a PDE10 inhibitor of Formula (I). Also disclosed are crystalline solid forms of the compound of Formula (I) and

Substituted heteroaryl compounds and compositions and uses thereof (by machine translation)

The invention discloses substituted heteroaryl compounds and compositions thereof and their use. The compounds of formula (I) compound or type shown in (I) a compound represented by stereo isomers, tautomers, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or its prodrug. The invention also provides a pharmaceutical composition, the compounds and pharmaceutical compositions can be regulated protein kinase, particularly Aurora kinase and JAK kinase activity, for the prevention, treatment, treatment and reduce protein kinase, in particular JAK kinase activity mediated diseases or disorders. (by machine translation)

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These

TRIAZOLOPYRIDINE COMPOUNDS

The invention is concerned with triazolopyridine compounds of formula (I), wherein R1, R2 , R3 and R4 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The

OXAZOLIDINONE DERIVATIVE HAVING FUSED RING

The present invention provides a novel antimicrobial drug comprising an oxazolidinone derivative of the formula (I): or a pharmaceutically acceptable salt or solvate thereof; wherein ring A is ring B is a benzene ring optionally substituted with lower alkyl; ring C is an optionally substituted six-membered heterocycle containing at least one nitrogen atom and one to three double bond(s) in the ling wherein the atom at the point of attachment to ring B is a carbon atom; ring D is an optionally substituted five-membered ring containing one or two double bond(s) in the ring; A1 and A2 are independently nitrogen or carbon; m is 0 or 1; R represents H, —NHC(═O)RA, —NHC(═S)RA, —NH-het1, —O-het1, —S-het1, —S(═O)-het1, —S(═O)2-het1, het2, —CONHRA, —OH, lower alkyl, lower alkoxy or lower alkenyl; and het1 and het2 are independently a heterocyclic group; with the proviso that the fused ring C-D is not